Back to top
more

ProNAi Therapeutics, Inc. (SRRA)

(Delayed Data from NSDQ)

$1.44 USD

1.44
339,733

+0.03 (2.13%)

Updated May 3, 2019 04:13 PM ET

After-Market: $1.44 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[SRRA]

Reports for Purchase

Showing records 1 - 20 ( 71 total )

Industry: Medical - Drugs

Record: 1

07/05/2022

Company Report

Pages: 6

Dropping Coverage; GSK Acquisition Complete

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 2

04/13/2022

Company Report

Pages: 8

MOMENTUM Goes the Distance; GlaxoSmithKline Acquires Sierra for $1.9B; Downgrade to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 3

03/10/2022

Company Report

Pages: 8

2021 Results; MOMENTUM Builds as NDA Submission Imminent; Focus on Pre-Commercialization Activities

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 4

01/31/2022

Company Report

Pages: 8

Sticking to Their Guns Pays Off in Spades as MOMENTUM Nails It; Price Target Upped to $51

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 5

01/18/2022

Daily Note

Pages: 6

Be Ready; MOMENTUM Data Now Expected by the End of January 2022

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 6

12/17/2021

Company Report

Pages: 7

Momelotinib About to Cross the Finish Line; MOMENTUM Pivotal Data Expected in February 2022

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 7

12/14/2021

Company Report

Pages: 8

ASH Data Highlights Baseline Ferritin as a Biomarker in Myelofibrosis

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 8

12/10/2021

Company Report

Pages: 7

Investor Meetings and Share Action Infer Palpable Excitement for February MOMENTUM Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 9

11/05/2021

Company Report

Pages: 6

3Q21 Results; No Slowing Down Here; MOMENTUM Top-Line Results on Track for Feb ''22

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 10

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for SRRA

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 11

08/09/2021

Daily Note

Pages: 4

Building MOMENTUM With Tightened Timeline; Phase 3 Data Not Far Off

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 12

08/06/2021

Company Report

Pages: 6

Building a Myelofibrosis Franchise and Beyond; 2Q21 Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 13

06/22/2021

Company Report

Pages: 6

A One-Two Therapeutic Punch; KOL Panel Highlights Momelotinib?s Efficacy in Myelofibrosis and Anemia Benefit

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 14

06/21/2021

Daily Note

Pages: 4

Momelotinib Checks Another Box; Pivotal Phase 3 Trial Enrollment Complete

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 15

06/14/2021

Company Report

Pages: 5

Momelotinib Heme Differentiation Continues at EHA

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 16

06/04/2021

Company Report

Pages: 7

Window Into Sierra''s Future? Could Be; Pivotal Data in 1Q22

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 17

05/07/2021

Company Report

Pages: 6

Pivotal Timing Set; Time to Pay Attention to Disruptive Momelotinib; 1Q21 Results

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 18

03/11/2021

Company Report

Pages: 6

2020 Results; MOMENTUM Getting Closer to Pivotal Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 19

12/17/2020

Company Report

Pages: 7

KOL Call Zeros in on Momelotinib''s Differentiated Safety and Efficacy Profile

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 20

12/11/2020

Company Report

Pages: 12

Transfer of Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party
// eof